HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diethanolamine added to CIR permanent agenda due to carcinogenic concerns.

This article was originally published in The Rose Sheet

Executive Summary

NTP DIETHANOLAMINE STUDY RESULTS "REQUIRE PROMPT ATTENTION," FDA Office of Cosmetics & Colors Director John Bailey, PhD, advised the Cosmetic Ingredient Review Expert Panel at a meeting in Washington, D.C. March 20. Following the agency's preliminary review of the National Toxicology Program's study on diethanolamine (DEA), Bailey concluded the findings were "very relevant" because of the "public health implications" and "significant enough" to "require prompt attention."
Advertisement

Related Content

DEA Carcinogenicity Evidence Limited To "One Study, One Species" - CTFA
DEA Carcinogenicity Evidence Limited To "One Study, One Species" - CTFA
Advertisement
UsernamePublicRestriction

Register

RS005260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel